Q32 Bio Inc. $QTTB Shares Purchased by Monaco Asset Management SAM

Monaco Asset Management SAM raised its holdings in shares of Q32 Bio Inc. (NASDAQ:QTTB) by 17.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 591,937 shares of the company’s stock after acquiring an additional 86,486 shares during the period. Monaco Asset Management SAM’s holdings in Q32 Bio were worth $882,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Nuveen LLC acquired a new position in shares of Q32 Bio during the first quarter valued at $92,000. AQR Capital Management LLC acquired a new stake in Q32 Bio in the first quarter worth about $68,000. Acadian Asset Management LLC bought a new position in Q32 Bio in the 1st quarter valued at about $50,000. Finally, Goldman Sachs Group Inc. increased its stake in Q32 Bio by 140.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock valued at $73,000 after buying an additional 25,953 shares during the period. Institutional investors own 31.32% of the company’s stock.

Q32 Bio Price Performance

NASDAQ QTTB opened at $2.26 on Friday. Q32 Bio Inc. has a 12 month low of $1.35 and a 12 month high of $48.65. The company has a market capitalization of $27.57 million, a P/E ratio of -0.53 and a beta of 0.15. The company’s 50 day simple moving average is $2.38 and its 200 day simple moving average is $2.01.

Q32 Bio (NASDAQ:QTTB) last issued its earnings results on Wednesday, August 6th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.36. On average, analysts anticipate that Q32 Bio Inc. will post -12.32 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on QTTB shares. Wall Street Zen raised shares of Q32 Bio from a “sell” rating to a “hold” rating in a research note on Sunday, October 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Q32 Bio in a report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Q32 Bio presently has a consensus rating of “Hold” and an average target price of $12.17.

Q32 Bio Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.